Skip to main content

Advertisement

SpringerLink
Log in

Kinase Mutations and Imatinib Mesylate Response for 64 Taiwanese with Advanced GIST: Preliminary Experience from Chang Gung Memorial Hospital

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutation of kit or platelet-derived growth factor receptor alpha (PDGFRA), which are therapeutic targets for imatinib. Results of 64 Taiwanese with advanced GIST treated with imatinib were reported.

Method and materials

Between 2001 and May 2006, a prospective, non-randomized, and a single center trial containing 64 Taiwanese patients with advanced GIST treated with imatinib was conducted. Each tumor was investigated for mutations of kit or PDGFRA.

Results

The median follow-up time after imatinib administration was 16.1 months. 12 patients (18.8%) had complete response (CR), 24 (37.5%) had a partial response (PR), 12 stationary disease (18.8%), 16 progressive disease (25.0%). The 64 Taiwanese with advanced GIST had an estimated median survival of 48.0 months and 4-year survival rate for 76.1%. Kit mutation was found in 49 of 54 (90.7%) test patients and five of them had no mutation (9.3%). No PDGFRA mutant was identified. In 40 patients harboring kit exon 11 mutations, the CR and PR rates (ORR) were 57.5% , nine patients with tumors containing kit exon 9 mutation had ORR rates of 22.2%, and five patients with no mutation had ORR rates of 60.0% (not significant; P = 0.149).

Conclusions

Activated mutation of kit constituted 90.7% genetic alteration of Taiwanese with advanced GIST and no PDGFRA mutation was detected. Imatinib induced a sustained objective response in more than half of Taiwan advanced GIST patients. ORR did not differ between patients whose GISTs had no mutation, kit exon 9, and 11 mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.

Similar content being viewed by others

REFERENCES

  1. Lewis JJ, Brennan MF. Soft tissue sarcoma. Curr Prob Surg 1996; 33(10):817–72

    Article  CAS  Google Scholar 

  2. Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003; 107:171

    Article  PubMed  CAS  Google Scholar 

  3. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51

    Article  PubMed  CAS  Google Scholar 

  4. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259–69

    PubMed  CAS  Google Scholar 

  5. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23:377–89

    Article  PubMed  CAS  Google Scholar 

  6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of tyrosine kinase inhibitor DTI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052–56

    Article  PubMed  CAS  Google Scholar 

  7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7):472–80

    Article  PubMed  CAS  Google Scholar 

  8. Yeh CN, Chen TW, Wu TJ, Jan YY, Chen MF. Treatment of patients with advanced gastrointestinal stromal tumor (GIST) of small bowel: Implications of imatinib mesylate. World J Gastroenterol 2006; 12(23):3760–5

    PubMed  CAS  Google Scholar 

  9. Akwari OE, Dozois RR, Weiland LH, Bearhrs OH. Leiomyosarcoma of the small and large bowel. Cancer 1978; 42:1375–84

    Article  PubMed  CAS  Google Scholar 

  10. Shiu MH, Farr GH, Papchristou DN, et al. Myosarcoma of the stomach: nature history, prognostic factors and management. Cancer 1982; 49:177–87

    Article  PubMed  CAS  Google Scholar 

  11. McGrath PC, Neifeld JP, Lawrence WJ, et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987; 206:706–10

    Article  PubMed  CAS  Google Scholar 

  12. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcoma. Implications for surgical management and staging. Ann Surg 1992; 215:68–77

    Article  PubMed  CAS  Google Scholar 

  13. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosin kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561–6

    Article  PubMed  CAS  Google Scholar 

  14. Buchdunger E, Cioffi C, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther2000; 295:139–45

    PubMed  CAS  Google Scholar 

  15. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925–32

    PubMed  CAS  Google Scholar 

  16. Wang WL, Healy ME, Satter M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19:3521–8

    Article  PubMed  CAS  Google Scholar 

  17. Green S, Weiss GR Southwest Oncology Group standard response criteria, end point definitions and toxicity criteria. Invest New Drugs 1992; 10:239–53

    Article  PubMed  CAS  Google Scholar 

  18. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23):4342–49

    Article  PubMed  CAS  Google Scholar 

  19. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br J Surg 2003; 90:332–9

    Article  PubMed  CAS  Google Scholar 

  20. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal tumors. Arch Surg 2001; 136:383–9

    Article  PubMed  CAS  Google Scholar 

  21. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistant proteins. J Clin Oncol 2000; 18:3211–20

    PubMed  CAS  Google Scholar 

  22. Rankin C, von Mehren M, Blanke C, et al. Continued prologation of survival by imatinib in patients with metastatic GIST. Update of results from North American Intergroup phase III study S0033. Proc Am Soc Clin Oncol 2004; 23:815–84 (Abstr 9005)

    Google Scholar 

  23. Zalcberg J. Proc Am Soc Clin Oncol 2004; 23:815. (Abstr 9004)

    Google Scholar 

  24. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal tumors. Science 2003; 299:708–10

    Article  PubMed  CAS  Google Scholar 

  25. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213–1220

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study appreciated Novartis (Taiwan) Co., Ltd for financial support of genetic analysis.

Author information

Authors and Affiliations

  1. Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu-Hsing Street, Kwei-Shan, Taoyuan, Taiwan

    Chun-Nan Yeh MD, Tsung-Wen Chen MD, Hsiang-Lin Lee MD, Yu-Yin Liu MD, Tzu-Chieh Chao MD, PhD, Tsann-Long Hwang MD, FACS, Yi-Yin Jan MD, FACS & Miin-Fu Chen MD, FACS

Authors
  1. Chun-Nan Yeh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsung-Wen Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hsiang-Lin Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-Yin Liu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tzu-Chieh Chao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsann-Long Hwang MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-Yin Jan MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miin-Fu Chen MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun-Nan Yeh MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeh, CN., Chen, TW., Lee, HL. et al. Kinase Mutations and Imatinib Mesylate Response for 64 Taiwanese with Advanced GIST: Preliminary Experience from Chang Gung Memorial Hospital. Ann Surg Oncol 14, 1123–1128 (2007). https://doi.org/10.1245/s10434-006-9288-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-006-9288-1

Keywords

Search

Navigation